Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 919
Filtrar
6.
Eur J Hum Genet ; 28(6): 719-723, 2020 06.
Artigo em Inglês | MEDLINE | ID: covidwho-261174

RESUMO

ELIXIR, the European research infrastructure for life science data, provides open access to data, tools and workflows in the response to the COVID-19 pandemic. ELIXIR's 23 nodes have reacted swiftly to support researchers in their combined efforts against the pandemic setting out three joint priorities: 1. Connecting national COVID-19 data platforms to create federated European COVID-19 Data Spaces; 2. Fostering good data management to make COVID-19 data open, FAIR and reusable over the long term; 3. Providing open tools, workflows and computational resources to drive reproducible and collaborative science. ELIXIR's strategy is based on the support given by our national nodes - collectively spanning over 200 institutes - to research projects and on partnering with community initiatives to drive development and adoption of good data practice and community driven standards. ELIXIR Nodes provide support activities locally and internationally, from provisioning compute capabilities to helping collect viral sequence data from hospitals. Some Nodes have prioritised access to their national cloud and compute facilities for all COVID-19 research projects, while others have developed tools to search, access and share all data related to the pandemic in a national healthcare setting.


Assuntos
Betacoronavirus/patogenicidade , Pesquisa Biomédica/organização & administração , Infecções por Coronavirus/epidemiologia , Disseminação de Informação/métodos , Cooperação Internacional/legislação & jurisprudência , Pandemias , Pneumonia Viral/epidemiologia , Betacoronavirus/genética , Infecções por Coronavirus/genética , Infecções por Coronavirus/patologia , Infecções por Coronavirus/virologia , Conjuntos de Dados como Assunto , Europa (Continente)/epidemiologia , Humanos , Disseminação de Informação/ética , Pneumonia Viral/genética , Pneumonia Viral/patologia , Pneumonia Viral/virologia , Saúde Pública/economia , Fluxo de Trabalho
7.
Eur J Hum Genet ; 28(6): 728-731, 2020 06.
Artigo em Inglês | MEDLINE | ID: covidwho-343660

RESUMO

During the COVID-19 pandemic, the European biobanking infrastructure is in a unique position to preserve valuable biological material complemented with detailed data for future research purposes. Biobanks can be either integrated into healthcare, where preservation of the biological material is a fork in clinical routine diagnostics and medical treatment processes or they can also host prospective cohorts or material related to clinical trials. The paper discussed objectives of BBMRI-ERIC, the European research infrastructure established to facilitate access to quality-defined biological materials and data for research purposes, with respect to the COVID-19 crisis: (a) to collect information on available European as well as non-European COVID-19-relevant biobanking resources in BBMRI-ERIC Directory and to facilitate access to these via BBMRI-ERIC Negotiator platform; (b) to help harmonizing guidelines on how data and biological material is to be collected to maximize utility for future research, including large-scale data processing in artificial intelligence, by participating in activities such as COVID-19 Host Genetics Initiative; (c) to minimize risks for all involved parties dealing with (potentially) infectious material by developing recommendations and guidelines; (d) to provide a European-wide platform of exchange in relation to ethical, legal, and societal issues (ELSI) specific to the collection of biological material and data during the COVID-19 pandemic.


Assuntos
Betacoronavirus/patogenicidade , Pesquisa Biomédica/organização & administração , Infecções por Coronavirus/epidemiologia , Disseminação de Informação/métodos , Cooperação Internacional/legislação & jurisprudência , Pandemias , Pneumonia Viral/epidemiologia , Antivirais/uso terapêutico , Inteligência Artificial , Betacoronavirus/efeitos dos fármacos , Betacoronavirus/genética , Bancos de Espécimes Biológicos/provisão & distribução , Ensaios Clínicos como Assunto , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/genética , Conjuntos de Dados como Assunto , Europa (Continente)/epidemiologia , Humanos , Disseminação de Informação/ética , Pneumonia Viral/diagnóstico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/genética , Guias de Prática Clínica como Assunto , Saúde Pública/economia
9.
Eur J Hum Genet ; 28(6): 719-723, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32415272

RESUMO

ELIXIR, the European research infrastructure for life science data, provides open access to data, tools and workflows in the response to the COVID-19 pandemic. ELIXIR's 23 nodes have reacted swiftly to support researchers in their combined efforts against the pandemic setting out three joint priorities: 1. Connecting national COVID-19 data platforms to create federated European COVID-19 Data Spaces; 2. Fostering good data management to make COVID-19 data open, FAIR and reusable over the long term; 3. Providing open tools, workflows and computational resources to drive reproducible and collaborative science. ELIXIR's strategy is based on the support given by our national nodes - collectively spanning over 200 institutes - to research projects and on partnering with community initiatives to drive development and adoption of good data practice and community driven standards. ELIXIR Nodes provide support activities locally and internationally, from provisioning compute capabilities to helping collect viral sequence data from hospitals. Some Nodes have prioritised access to their national cloud and compute facilities for all COVID-19 research projects, while others have developed tools to search, access and share all data related to the pandemic in a national healthcare setting.


Assuntos
Betacoronavirus/patogenicidade , Pesquisa Biomédica/organização & administração , Infecções por Coronavirus/epidemiologia , Disseminação de Informação/métodos , Cooperação Internacional/legislação & jurisprudência , Pandemias , Pneumonia Viral/epidemiologia , Betacoronavirus/genética , Infecções por Coronavirus/genética , Infecções por Coronavirus/patologia , Infecções por Coronavirus/virologia , Conjuntos de Dados como Assunto , Europa (Continente)/epidemiologia , Humanos , Disseminação de Informação/ética , Pneumonia Viral/genética , Pneumonia Viral/patologia , Pneumonia Viral/virologia , Saúde Pública/economia , Fluxo de Trabalho
10.
Eur J Hum Genet ; 28(6): 728-731, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32444797

RESUMO

During the COVID-19 pandemic, the European biobanking infrastructure is in a unique position to preserve valuable biological material complemented with detailed data for future research purposes. Biobanks can be either integrated into healthcare, where preservation of the biological material is a fork in clinical routine diagnostics and medical treatment processes or they can also host prospective cohorts or material related to clinical trials. The paper discussed objectives of BBMRI-ERIC, the European research infrastructure established to facilitate access to quality-defined biological materials and data for research purposes, with respect to the COVID-19 crisis: (a) to collect information on available European as well as non-European COVID-19-relevant biobanking resources in BBMRI-ERIC Directory and to facilitate access to these via BBMRI-ERIC Negotiator platform; (b) to help harmonizing guidelines on how data and biological material is to be collected to maximize utility for future research, including large-scale data processing in artificial intelligence, by participating in activities such as COVID-19 Host Genetics Initiative; (c) to minimize risks for all involved parties dealing with (potentially) infectious material by developing recommendations and guidelines; (d) to provide a European-wide platform of exchange in relation to ethical, legal, and societal issues (ELSI) specific to the collection of biological material and data during the COVID-19 pandemic.


Assuntos
Betacoronavirus/patogenicidade , Pesquisa Biomédica/organização & administração , Infecções por Coronavirus/epidemiologia , Disseminação de Informação/métodos , Cooperação Internacional/legislação & jurisprudência , Pandemias , Pneumonia Viral/epidemiologia , Antivirais/uso terapêutico , Inteligência Artificial , Betacoronavirus/efeitos dos fármacos , Betacoronavirus/genética , Bancos de Espécimes Biológicos/provisão & distribução , Ensaios Clínicos como Assunto , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/genética , Conjuntos de Dados como Assunto , Europa (Continente)/epidemiologia , Humanos , Disseminação de Informação/ética , Pneumonia Viral/diagnóstico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/genética , Guias de Prática Clínica como Assunto , Saúde Pública/economia
12.
Am J Trop Med Hyg ; 102(6): 1181-1183, 2020 06.
Artigo em Inglês | MEDLINE | ID: covidwho-596857

RESUMO

Novel coronavirus disease (COVID-19), named a pandemic by the WHO, is the current global health crisis. National and international collaboration are indispensable for combating COVID-19 and other similar potential outbreaks. International efforts to tackle this complex problem have led to remarkable scientific advances. Yet, as a global society, we can and must take additional measures to fight this pandemic. Undoubtedly, our approach toward COVID-19 was not perfect, and testing has not been deployed fast enough to arrest the epidemic early on. It is critical that we revise our approaches to be more prepared for pandemics as a united body by promoting global cooperation and commitment.


Assuntos
Betacoronavirus/patogenicidade , Defesa Civil/organização & administração , Infecções por Coronavirus/epidemiologia , Cooperação Internacional/legislação & jurisprudência , Pandemias , Pneumonia Viral/epidemiologia , Antivirais/síntese química , Antivirais/uso terapêutico , Ásia/epidemiologia , Betacoronavirus/efeitos dos fármacos , Técnicas de Laboratório Clínico/normas , Técnicas de Laboratório Clínico/estatística & dados numéricos , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/prevenção & controle , Europa (Continente)/epidemiologia , Humanos , Oriente Médio/epidemiologia , Pandemias/prevenção & controle , Pneumonia Viral/diagnóstico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/prevenção & controle , Vacinas Virais/biossíntese , Vacinas Virais/uso terapêutico
13.
Am J Trop Med Hyg ; 102(6): 1181-1183, 2020 06.
Artigo em Inglês | MEDLINE | ID: covidwho-108902

RESUMO

Novel coronavirus disease (COVID-19), named a pandemic by the WHO, is the current global health crisis. National and international collaboration are indispensable for combating COVID-19 and other similar potential outbreaks. International efforts to tackle this complex problem have led to remarkable scientific advances. Yet, as a global society, we can and must take additional measures to fight this pandemic. Undoubtedly, our approach toward COVID-19 was not perfect, and testing has not been deployed fast enough to arrest the epidemic early on. It is critical that we revise our approaches to be more prepared for pandemics as a united body by promoting global cooperation and commitment.


Assuntos
Betacoronavirus/patogenicidade , Defesa Civil/organização & administração , Infecções por Coronavirus/epidemiologia , Cooperação Internacional/legislação & jurisprudência , Pandemias , Pneumonia Viral/epidemiologia , Antivirais/síntese química , Antivirais/uso terapêutico , Ásia/epidemiologia , Betacoronavirus/efeitos dos fármacos , Técnicas de Laboratório Clínico/normas , Técnicas de Laboratório Clínico/estatística & dados numéricos , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/prevenção & controle , Europa (Continente)/epidemiologia , Humanos , Oriente Médio/epidemiologia , Pandemias/prevenção & controle , Pneumonia Viral/diagnóstico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/prevenção & controle , Vacinas Virais/biossíntese , Vacinas Virais/uso terapêutico
14.
Am J Trop Med Hyg ; 102(6): 1181-1183, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32323644

RESUMO

Novel coronavirus disease (COVID-19), named a pandemic by the WHO, is the current global health crisis. National and international collaboration are indispensable for combating COVID-19 and other similar potential outbreaks. International efforts to tackle this complex problem have led to remarkable scientific advances. Yet, as a global society, we can and must take additional measures to fight this pandemic. Undoubtedly, our approach toward COVID-19 was not perfect, and testing has not been deployed fast enough to arrest the epidemic early on. It is critical that we revise our approaches to be more prepared for pandemics as a united body by promoting global cooperation and commitment.


Assuntos
Betacoronavirus/patogenicidade , Defesa Civil/organização & administração , Infecções por Coronavirus/epidemiologia , Cooperação Internacional/legislação & jurisprudência , Pandemias , Pneumonia Viral/epidemiologia , Antivirais/síntese química , Antivirais/uso terapêutico , Ásia/epidemiologia , Betacoronavirus/efeitos dos fármacos , Técnicas de Laboratório Clínico/normas , Técnicas de Laboratório Clínico/estatística & dados numéricos , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/prevenção & controle , Europa (Continente)/epidemiologia , Humanos , Oriente Médio/epidemiologia , Pandemias/prevenção & controle , Pneumonia Viral/diagnóstico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/prevenção & controle , Vacinas Virais/biossíntese , Vacinas Virais/uso terapêutico
15.
Nature ; 580(7802): 232-234, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32269340

RESUMO

Environmental change is rapidly accelerating, and many species will need to adapt to survive1. Ensuring that protected areas cover populations across a broad range of environmental conditions could safeguard the processes that lead to such adaptations1-3. However, international conservation policies have largely neglected these considerations when setting targets for the expansion of protected areas4. Here we show that-of 19,937 vertebrate species globally5-8-the representation of environmental conditions across their habitats in protected areas (hereafter, niche representation) is inadequate for 4,836 (93.1%) amphibian, 8,653 (89.5%) bird and 4,608 (90.9%) terrestrial mammal species. Expanding existing protected areas to cover these gaps would encompass 33.8% of the total land surface-exceeding the current target of 17% that has been adopted by governments. Priority locations for expanding the system of protected areas to improve niche representation occur in global biodiversity hotspots9, including Colombia, Papua New Guinea, South Africa and southwest China, as well as across most of the major land masses of the Earth. Conversely, we also show that planning for the expansion of protected areas without explicitly considering environmental conditions would marginally reduce the land area required to 30.7%, but that this would lead to inadequate niche representation for 7,798 (39.1%) species. As the governments of the world prepare to renegotiate global conservation targets, policymakers have the opportunity to help to maintain the adaptive potential of species by considering niche representation within protected areas1,2.


Assuntos
Conservação dos Recursos Naturais/legislação & jurisprudência , Ecossistema , Política Ambiental/legislação & jurisprudência , Internacionalidade , Animais , Biodiversidade , Governo Federal , Cooperação Internacional/legislação & jurisprudência , Tamanho da Amostra
17.
PLoS One ; 15(3): e0229555, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32160207

RESUMO

A significant challenge of conservation biology is to preserve species in places where their critical habitat also attracts significant economic interest. The problem is compounded when species distributions occur across large spatial extents. Threatened boreal caribou (Rangifer tarandus caribou) epitomize this problem: their critical habitat encompasses a vast expanse of forest that also supplies much of Canada's merchantable timber. Boreal caribou were protected under the Canada Species at Risk Act in 2003. We investigated putative drivers of reduced disturbance for caribou habitat since then. Where the cumulative logging footprint slowed within caribou habitat, this has resulted neither from decreases in annual allowable cut of timber nor the creation or expansion of protected areas. Rather, it has fluctuated with the American economy relative to that of Canada. For each $0.05 US lost over the $CAD, 129 km2 of caribou habitat was not disturbed by logging in a given year. Recent population declines have been occurring even though logging typically remained at <70% of allowed levels. Our study raises concerns about how caribou are functionally being conserved under the current application of existing legislation. In this globalized world, the economy of foreign nations is increasingly likely to govern national conservation objectives.


Assuntos
Conservação dos Recursos Naturais/economia , Espécies em Perigo de Extinção/economia , Cooperação Internacional/legislação & jurisprudência , Animais , Canadá , Conservação dos Recursos Naturais/métodos , Ecossistema , Florestas , Dinâmica Populacional , Rena , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA